+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tofacitinib"

Tofacitinib Market Report 2025 - Product Thumbnail Image

Tofacitinib Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Rheumatology Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Rheumatology Therapeutics - Global Strategic Business Report

  • Report
  • April 2025
  • 196 Pages
  • Global
From
Janus Kinase (JAK) Inhibitors Market Report 2025 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitors Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 180 Pages
  • Global
From
From
From
Psoriatic Arthritis - Pipeline Insight, 2024 - Product Thumbnail Image

Psoriatic Arthritis - Pipeline Insight, 2024

  • Clinical Trials
  • December 2024
  • 80 Pages
  • Global
From
JAK Inhibitors Market - Product Thumbnail Image

JAK Inhibitors Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
From
US Axial Spondyloarthritis Market outlook to 2028 - Product Thumbnail Image

US Axial Spondyloarthritis Market outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
From
Psoriatic Arthritis Treatment Global Market Report 2024 - Product Thumbnail Image

Psoriatic Arthritis Treatment Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Tofacitinib Global Market Opportunities and Strategies to 2032 - Product Thumbnail Image

Tofacitinib Global Market Opportunities and Strategies to 2032

  • Report
  • January 2024
  • 244 Pages
  • Global
From
From
JAK inhibitors - Competitive Landscape, 2023 - Product Thumbnail Image

JAK inhibitors - Competitive Landscape, 2023

  • Report
  • April 2023
  • 180 Pages
  • Global
From
XELJANZ Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

XELJANZ Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
Loading Indicator

Tofacitinib is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a Janus kinase (JAK) inhibitor, which works by blocking the action of certain enzymes that are involved in the body's inflammatory response. Tofacitinib is taken orally, usually twice daily. It is available in both tablet and solution form. Tofacitinib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It is the first JAK inhibitor to be approved for the treatment of immune disorders. Since its approval, it has become a popular treatment option for many patients. The market for Tofacitinib is highly competitive, with several companies offering the drug. These include Pfizer, Novartis, AbbVie, and Merck. Each company has its own formulation of the drug, and they compete on price, efficacy, and safety. Show Less Read more